Purpose: Herein, we introduce a methodology for estimating the absorbed dose in organs at risk that is based on specified clinically derived radiopharmaceutical biodistributions and personalized anatomical characteristics. Methods: To evaluate the proposed methodology, we used realistic Monte Carlo (MC) simulations and computational pediatric models to calculate a parameter called in this work the "specific absorbed dose rate" (SADR). The SADR is a unique quantitative metric in that it is specific to a particular organ. It is defined as the absorbed dose rate in an organ when the biodistribution of radioactivity over the whole body is considered. Initially, we applied a validation procedure that calculated specific absorbed fractions (SAFs) from mono-energetic photon sources in the range of 10 keV-2 MeV and compared them with previously published data. We calculated the SADRs for five different radiopharmaceuticals ( 99m Tc-MDP, 123 I-mIBG, 131 I-MIBG, 131 I-NaI, and 153 Sm-EDTMP) based on their biodistributions at four or five different times; the biodistributions were derived from the clinical scintigraphic data of pediatric patients. We used six models representing male and female patients aged 5, 8, and 14 yr to investigate the absorbed dose variability due to anatomical variations. The GATE Monte Carlo toolkit was used to calculate absorbed doses per organ. Finally, we compared the SADR methodology to that of OLINDA/EXM 1.1 using rescaled masses according to the studied models. Four target organs were considered for calculating the absorbed doses. Results: The ratios of SAFs calculated with GATE simulations to those based on previously published data were between 0.9 and 2.2 when the liver was used as a source organ. Subsequently, we used GATE to calculate a dataset of SADRs for the six pediatric models. The SADRs for pediatric models whose total body weights ranged from 20 to 40 kg varied up to approximately 90%, whereas those for models of similar body masses varied less than 15%. Finally, we found absorbed dose discrepancies of approximately 10-150% between the SADR methodology and OLINDA for two different radiopharmaceuticals. Absorbed doses from SADRs and from individualized S-values in the same pediatric model differed approximately 1-50%. Conclusions: Because pediatric radiopharmaceutical dosimetric estimates demonstrate large variation due to the patient's anatomical characteristics, personalized data should be considered. Using our SADR method in a larger population of phantoms and for a variety of radiopharmaceuticals could enhance the personalization of dosimetry in pediatric nuclear medicine. The proposed methodology provides the advantage of creating time-dependent organ dose rate curves.
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INTRODUCTION
Nuclear medicine (NM) is a well-established technique used for diagnosis and therapy in pediatric patients. Patient-specific internal dosimetry is of great interest in children and adolescents, whose relative risk from exposure to ionizing radiation compared with adults is widely debated. 1 Children are considered to be more radiosensitive than adults, as they may experience greater stochastic effects due to a higher percentage of replicating cells. 2 The real and potential risks of low-level ionizing radiation exposure from NM procedures in children remain controversial. 3, 4 Thus, ways to minimize the administered radiation dose while retaining acceptable image quality of standalone examinations, such as gamma camera planar imaging and single photon emission computed tomography, (SPECT) and hybrid examinations, such as SPECT/ computed tomography (CT) and PET/CT, have been an intense area of discussion over the past two decades.
The absorbed radiation dose resulting from diagnostic and therapeutic NM procedures in pediatric patients is a matter of concern.
5-7 Portelli et al. 8 recently assessed the frequency of pediatric medical imaging examinations over 7 yr and found that each year, 4 of every 1,000 pediatric patients in the United States likely undergo an NM examination. 8 The frequency of NM examinations is lower than that of other medical imaging modalities in this population; nevertheless, NM procedures should be performed with the lowest possible amount of administered activity necessary to ensure a useful diagnostic result. NM acquisitions are considered to be relatively high-dose diagnostic examinations for children; for example, the estimated effective 18 F-fluorodeoxyglucose dose in such examinations for children aged 1-15 yr ranges from 8.0 to 9.2 mSv, and that for 82 RbCl ranges from 8.3 to 9.9 mSv. 9 To provide the best administered activities while reducing the absorbed dose in pediatric patients, we must determine the method by which such activities should be calculated, the correct reference anatomic models, and the maximum tolerated administered activity. 10 Thus, the calculation of the activity that should be administered in pediatric patients must be optimized by considering the anatomical and physiological characteristics of each patient. The assessment of the impact of the dose in a target organ should take into account the deposited energy from every other organ. In 2006, the European Association of Nuclear Medicine (EANM) published a pediatric dosage card for 39 radiopharmaceuticals, which was amended in 2008. 11, 12 Accordingly, in 2011, the Pediatric Nuclear Medicine Dose Reduction Workgroup recommended the North American consensus guidelines for radiopharmaceutical administered dosages. 10 In 2014, a harmonization between the EANM dosage card and the Society of Nuclear Medicine and Molecular Imaging guidelines on pediatric radiopharmaceutical administration was published. 13 Dosimetry in the context of radiation risk assessment requires the determination of reference levels of irradiation for every radiopharmaceutical and the provision of absorbed dose estimates in clinical practice. 14 The assessment of the cumulative radiation dose from NM diagnostic procedures to children is performed using the dosimetric parameters and mathematical phantoms reported in International Commission on Radiological Protection publications [15] [16] [17] and MIR-DOSE 18 or OLINDA 19 software. Physical models and Svalues based on Medical Internal Radiation Dose (MIRD) Committee schema were reported by Stabin and Siegel, 20 whereas MIRD Pamphlet No. 17 introduced the dosimetry of nonuniform activity distributions at the voxel level. 21 However, several dosimetry studies have revealed significant differences between stylized and voxel-based phantoms and between models with organ-level variations. [22] [23] [24] [25] Organ-level internal dosimetry in NM currently relies on the MIRD Committee schema, 26 as it is defined in Eqs. (1) and (2):
where D(r T ) is the cumulative absorbed dose to a particular target organ,Ã(r s ) is the time integrated (previously called cumulated) activity in a source organ, and S is the so-called S-value representing the mean dose to the target organ per disintegration in the source organ. The parameter E i is the individual energy of the ith radiation, Y i is the associated yield per nuclear transformation, and Φ i (r T r s ) is the associated specific absorbed fraction (SAF) for the source-target organ pair. The OLINDA/EXM MIRD software code, 19 which is based on the RADAR (RAdiation Dose Assessment Resource) system, 20, 27 is the more widely used methodology for calculating internal radionuclide radiation dose.
The evolution of computer science and the need for accurate anatomical modeling of patients led to the creation of computational population phantoms specialized for different kinds of applications. The first attempt by Snyder and Fisher 28 to develop computational anthropomorphic models based on simple geometrical shapes dates back to the 1960s. Two decades later, Oak Ridge National Laboratories reported the development of a new series of stylized phantoms, including pediatric models, which were widely adopted in the NM dosimetry community. 29 Using the Monte Carlo (MC) method to reproduce a clinical study requires the simulation of large populations of computational models to approach patient-specific dosimetry. Within this scope, the University of Florida introduced a family of reference hybrid phantoms, including a series of six pediatric models, in a voxelized format that allows the scalability of their anatomy. 30 Later, Norris et al. developed a set of four-dimensional (4D) realistic pediatric models based on the hybrid extended cardiac-torso (XCAT) phantom and the use of nonuniform rational Bsplines (NURBS) that incorporate organ motion, such as respiratory and cardiac motion. 31 More recently, Xie et al. used several pediatric computational phantoms for dosimetric assessment, which included calculating S-values for a variety of PET radionuclides and investigating the impact of changes in body weight on the estimation of the SAFs from which the S-values were derived. 1 Medical Physics, 45 (8) , August 2018 In this context, it is essential to accurately assess the radiation dose delivered to each organ of interest for NM procedures performed on children. We propose a method for calculating the absorbed dose per organ that takes into account each patient's specific anatomy and calculates "specific absorbed dose rates" (SADRs) for each organ according to the specific biodistribution of each radiopharmaceutical. Our long-term goal is to use the proposed method to establish a large database of SADRs, which will be used as a reference for the classification of each patient NM procedure.
MATERIALS AND METHODS

2.A. MC simulations
The absorbed dose calculations for this study were based on the Geant4 (GEometry ANd Tracking) Application for Tomographic Emission (GATE) MC toolkit 32, 33 using the Geant4 simulation toolkit (v9.5) code. 34 All simulations applied the "standard model" in GATE for electromagnetic processes, which is effective and validated over an energy range of 1 keV-100 TeV. The absorbed dose per organ was calculated, and the deposited energy per voxel was stored using the "dose actor" tool in GATE. The dose actor builds three-dimensional images of the deposited energy in a given volume with a specified voxel resolution. The dose actor takes into account the total energy and the interaction probability of the particles, as well as the density of each voxel. Accordingly, the relative statistical uncertainty per voxel was calculated and extracted for a few simulated cases. Equation (3) defines the statistical uncertainty e k at voxel k, with N being the number of primary events and d k,i the deposited energy in voxel k for primary event i:
To achieve a statistical uncertainty of less than 5% in most organs we executed the simulations in the GateLab computing grid infrastructure. 35 The GATE has been previously validated for NM dosimetry applications using both photon and electron emitters. 36, 37 We performed a validation step for the GATE simulations on internal dosimetry using an adult XCAT reference model and a model representing a 5-yr-old boy and by calculating the SAFs for a photon energy range of 10 keV-3 MeV. 38 This procedure validated the tools used in this study for further extracting the S-values and SADRs for several radiopharmaceuticals.
2.B. Anthropomorphic models
We used anthropomorphic computational phantoms to model the pediatric anatomy. Six different phantoms were used to estimate the dosimetric differences at the macroscopic organ level. The phantoms used were derived from a series of 4D pediatric XCAT reference models 31 and the IT'IS Virtual Family models. 39 The details of the pediatric phantoms used in the study are given in Table I . The voxel resolution on each phantom was 2.0 9 2.0 9 2.0 mm. The masses of the organs of interest in the six phantoms are given in Table II. The models imported into GATE served both as radiation transport media and activity maps. The transport media take into account the density and elemental composition of each organ, with materials that are predefined in GateMaterials.db. The activity was assigned homogeneously, taking into account the mean activity within each organ of interest as a function of time based on the biodistribution of each radiopharmaceutical.
2.C. Clinical biodistributions
The proposed method for the SADR calculation employed clinically derived biodistributions from pediatric scintigraphy studies. Specifically, the exams of five pediatric patients (patients A-E; age 7-17 yr) were used to extract the biodistributions of commonly used radiopharmaceuticals. Only retrospective, completely anonymized, numeric radiopharmaceutical dosimetry data were used. Manual region of interest (ROI) segmentation was applied to the whole-body planar images at four or five different times after radiopharmaceutical administration to extract the time activity curves of the organs of interest. We extracted the clinical biodistributions of the following radiopharmaceuticals: 131 I-NaI biodistributions were calculated using the exams of an 8-yr-old boy and a 14-yr-old girl. In addition, dosimetry for 131 I-mIBG was investigated using the biological (decay-corrected) data derived from the 123 I-mIBG exam. I-mIBG have identical biodistributions. Thus, the respective energy spectra were used in each simulation to calculate the dosimetry for both radiopharmaceuticals. In all five patient exams, one scan was acquired 0-1 h before urination. Subsequently, scans were acquired at 4, 24, and 48 h ( 123 I-mIBG); 4, 24, 48, and 72 h ( 131 I-NaI); and 2, 4, and 24 h ( 99m Tc-MDP and 153 Sm-EDTMP). The geometric mean of background-corrected anterior and posterior ROI count rates was calculated for all organs showing activity above background levels. For the 123 I-mIBG exam, reference standard source sensitivity calibration and cobalt-57 sheet source transmission image attenuation (converted to 123 I) correction were applied, and organ activity was normalized to injected activity. For the other four exams, organ count rates were normalized to the immediate total body ROI geometric mean count rate, which was assumed to represent an attenuated activity reference standard containing 100% of the injected activity. In the case of right kidney overlap with liver, the left kidney-only count rate was scaled by the ratio of left plus right kidney masses to left-only kidney mass to estimate the total kidney count rate. Heart overlap was excluded from the left lung ROI. (There were no other instances of organ or organ/tumor overlap in the five exams). For all clinical data, exponential function curve fits (either 1-or 2-phase clearance, or uptake and clearance phase) were applied to the extracted fraction of the time activity curves of the injected radiopharmaceutical using in-house analysis software.
2.D. Dosimetry procedure and SADR calculation
The MC simulations provide the ground truth for internal dosimetry in NM and in targeted radionuclide therapy. 40 Several approaches have been developed for the determination of the cumulative absorbed dose, which has been analytically described in the review study by Stabin. 41 The use of the S-value approach facilitates the calculation of the absorbed dose per organ due to the irradiation contribution of the organ's own radioactivity (self S-value) or due to the irradiation from other organs containing radioactivity (cross S-value). In our approach, we use the SADR metric, which considers the radioactivity distributed throughout the whole body (i.e., the organ's own radioactivity as well as all other organs' radioactivity), to calculate the absorbed dose per organ. The absorbed doses at several times were calculated according to the biodistribution of each radiopharmaceutical. In these cases, the radiopharmaceutical biodistributions were known, and different simulations were applied for several times after injection.
The SADRs provide the instantaneous absorbed dose rate in a target organ from the activity of all organs throughout the body (acting as source organs simultaneously) based on a specific biodistribution defined at time t k .
where r WB is the whole-body source, E di is the energy of the ith radiation per disintegration deposited in target organ r T and m rT is the mass of the target organ; and Y i is the yield per disintegration on the t k biodistribution. The absorbed dose to a target organ during a NM examination (t D = t final À t 0 ) is given by Eq. (5):
where A r WB ; t D ð Þis the instantaneous whole-body activity on the specific t k biodistribution. Based on the t k biodistribution and the duration (t D ) of the activity within the body, the integration of the SADRs for each target organ, on several times (t k ) of the radiopharmaceutical biodistributions, provide the cumulative absorbed dose.
This procedure provides the absorbed dose rate from all sources of radioactivity distribution within the body in every organ of interest at a specific time. Thus, the term SADR is used to derive the cumulative dose in each organ. Simulating four or five different biodistributions and extracting the SADRs as a function of time, the absorbed dose rate is known, and fitting curves can be applied to compute the cumulative absorbed dose for the whole time the radionuclide remains in the body. The procedure for calculating SADRs is depicted in Fig. 1 . Initially, the GATE MC toolkit was validated for extracting previously reported photon S-values over an energy range of 10 keV-3 MeV. The photon emission spectrum was considered for the SADRs extraction simulating six different pediatric models. The Results section describes a comparison of the estimation of the absorbed dose per organ for a specific patient (phantom 1) between the SADR approach and the OLINDA software. Individualized S-values for phantom 1 were calculated to further compare the SADR metric with Svalues derived in the same model. Finally, the effects of the anatomical variations between the models on the SADR calculation are presented in histograms in the Supporting Information (e.g., "SADRs_Supplemental_Material.xlsx"). 42 To standardize the SADR methodology, we considered the photon emission contribution, but not the beta contribution, of each radionuclide. The photon spectra of the radiopharmaceuticals were derived from the NuDat library (Nuclear Structure and Decay Data -National Nuclear Data Center). 43 The photon spectra were imported into GATE as a source (a-user-defined histogram) defining the emission possibilities of each energy. The spectrums used for each radionuclide are explicitly described in the Supporting Information (e.g., "SADRs_Supplemental_Material.xlsx"). 42 
RESULTS
3.A. Validation with GATE MC internal dosimetry
The validation procedure of GATE for the extraction of dosimetric parameters, was performed by calculating the SAFs, as defined in Eq. (2). The mono-energetic photon emissions were taken into consideration, comparing the results of the current study of GATE MC toolkit with previously published data using the Geant4 code. 38 The results of the SAF comparisons using the liver as the source organ are shown in Fig. 2 . For an adult male phantom, the SAFs from liver to kidneys had a mean error of 2.53%; from liver to liver, a mean error of 1.03%; and from liver to lungs, a mean error of 17.06% [Figs. 2(a)-2(c)]. In the latter case, the 10-keV photons had a maximum error of 54.61%, which was due to the very low density of the lungs, where small variations between the phantoms and the total mass of the lungs can lead to larger discrepancies. Furthermore, for a phantom representing a 5-yr-old boy, the SAFs from the liver to kidneys had a mean error of 4.14% [ Fig. 2(d) ]. The ratios between all the SAFs calculated in our study (numerator) and those published previously (denominator) are presented in Fig. 3 . With the exception of a ratio of 2.2 for the SAF from the liver to lungs at 10 keV in the adult male phantom, all ratios were between 0.9 and 1.2.
3.B. Clinical biodistributions of radiopharmaceuticals and extraction of SADRs
The biodistributions of the five radiopharmaceuticals ( 99m Tc-MDP, 123 I-MIBG, 131 I-MIBG, 131 I-NaI, and 153 Sm-EDTMP) were used as input in the MC simulations and served as activity maps in the phantoms. The 131 I-NaI distribution was derived from patients C and D. Thus, SADRs were extracted for 131 I-NaI in patient A and 131 I-NaI in patient B. The six different biodistributions were used in six pediatric computational models (Table I ). The photon energy spectrum for each radionuclide was derived from the National Nuclear Data Center. 43 SADRs were extracted for 21 organs of interest, namely the adrenal glands, urinary bladder, brain, bones, heart, kidneys, liver, lungs, salivary glands, gallbladder, large intestine, small intestine, stomach, pancreas, red marrow, spleen, testes/ovaries, uterus, thyroid, thymus, and remainder of the body. The SADRs were extracted at four or five different times according to the radiopharmaceutical biodistribution. All biodistribution data, including the clinically used biodistributions for each time and all the respective SADRs, are presented in the Excel file "SADRs_ Supplemental_Material.xlsx" 42 as Supporting Information. Each radiopharmaceutical is presented in a separate worksheet.
All the simulations were executed with approximately 10 8 primaries to achieve low statistical uncertainty. For most organs, the statistical uncertainty was approximately 5%; however, the statistical uncertainty reached approximately 10% in small organs and low-density organs such as the thymus and lungs. Histograms were created to visualize variations in SADRs due to the different anatomies of the several pediatric phantoms employed in the study. Histograms showing variations in the SADRs immediately after injection (0 h) for three of the radiopharmaceuticals are presented in Fig. 4 . Comparing the different phantoms revealed that larger differences in the anatomies of the models resulted in larger variations between the SADRs, which reached 90% in certain organs. In contrast, models representing patients of similar age and weight, such as those representing an 8-yr-old boy (25.6 kg) and an 8-yr-old girl (29.6 kg), had SADR differences of less than 15% in most organs, as in the case of 153 Sm-EDTMP. To investigate the impact anatomical variations have on SADRs and S-values, we executed a set of simulations calculating individualized S-values for the two models that had the largest differences in anatomy (phantoms 1 and 5). S-values were calculated for 99m Tc using the liver or spleen as a source. Target organs were the kidneys, liver, spleen, and brain. The SADRs of these target organs varied up to 90% in these two models, while the largest difference was approximately 70% for S-value liver?brain .
3.C. Comparison of SADRs and OLINDA values
We evaluated our SADR method by comparing the resulting organ absorbed doses with those resulting from S-values in OLINDA for two specific cases published previously. The SADRs of an 11-kg 5-yr-old boy were used for the dosimetry, assuming an injected activity (according to the EANM dosage card) of 110 MBq for Tc-MDP and 123 I-mIBG doses per organ were calculated for 20.3 and 45 h after injection, respectively. The activity was considered at each time, and the absorbed dose rate was integrated over the SADR curves. The biodistributions used in the MC simulations were accordingly entered into the OLINDA software. The calculated OLINDA dose factors were corrected for the organ masses of the phantom and then used to calculate the cumulative organ absorbed dose. In addition, individualized S-values were calculated for both cases to further validate the SADR methodology. Comparison was applied using the absorbed dose per organ derived from the new S-values that were calculated in the same pediatric model for which the SADRs were calculated.
The absorbed doses for the two cases are summarized in Table III , which shows differences between OLINDA values and SADRs ranging from 10.5% to 159.8% for four specific target organs of interest, namely the kidneys, liver, spleen, and brain. Differences between the dose extracted from individualized S-values and the SADRs in the same model were much lower, ranging from 1.5% to 46.5%. In all cases, the same biodistribution (source organs) was incorporated to extract the absorbed doses. The ratios of the comparative values (calculated organ absorbed doses in mGy) between the OLINDA values (denominator) and SADRs (nominator) ranged from 0.4 to 2.6, and between individualized S-values (denominator) and SADRs (nominator) ranged from 0.5 to 1.1. The ratios are presented in Figs. 5(a) and 5(b), respectively.
DISCUSSION
The objective of this study was to standardize a method for more personalized internal radionuclide dosimetry in pediatric NM applications. The MIRD-based S-value methodology, which calculates organ absorbed doses based on pediatric anthropomorphic computational models at four specific ages, has been a well-established approach for more than 30 yr. In the present study, we introduced the SADR, which is based on the dose a target organ absorbs from all organs with radioactivity. The GATE toolkit, a well-validated code, was used to execute the MC dose simulations. Initially, GATE-based calculations of the internal doses were validated against previously published data. A comparison of derived SAFs for specific target and source organ combinations and a range of photon energies (10 keV-3 MeV) demonstrated GATE-to-previous data ratios of 0.9-1.2.
We used a set of pediatric computational models to study the effect of pediatric patients' anatomical variations on organ FIG. 3 . Ratios of the present study's GATE/XCAT SAFs to previously published Geant4/NURBS SAFs for source organ-target organ pairs in four phantoms (three adult and one pediatric).
Medical Physics, 45 (8), August 2018 absorbed doses. Clinically derived biodistributions were inserted into the models as activity-vs-time maps, and organ absorbed doses were calculated, taking into account the specified biodistribution of each radiopharmaceutical. Thus, SADRs were calculated for every organ of interest in different anatomical models (three boys and three girls aged 5-15 yr), for each radiopharmaceutical's biodistribution at four or five different times, and for the extraction of the dose rate for each organ.
The calculated SADRs differed up to 90% in specific organs among the different pediatric models. Lower differences (mean relative difference,~15-20%) were found Tc-MDP, the source organs were the bladder, kidneys, bones, and remainder of the body, whereas for 123 I-mIBG, the source organs were the bladder, heart, liver, kidneys, lungs, and remainder of the body.
Medical Physics, 45 (8) , August 2018 between models that were closer in anatomical morphology (based on total weight). As shown in Fig. 4 , all the organs exhibit a pattern with differences in similar range.
For the standardization of the proposed method, we compared organ absorbed doses for photon sources extracted from SADRs and the OLINDA/EXM software. Using two different radiopharmaceuticals, we found that the differences in the absorbed doses for a specific pediatric model (phantom 1; representing a 5-yr-old boy) varied 10-160%, with ratios of SADR doses to OLINDA doses of less than 2.6 for the organs of interest. In addition, in Fig. 5 we noticed that the higher differences between doses from OLINDA vs SADRs are depicted in organs that are not self-irradiating, such as liver (ratio 2.4), spleen (ratio 2.2), and brain (ratio 0.4) for 99m Tc, and spleen (ratio 2.6) and brain (ratio 0.7) for 123 I. Kidneys are involved in both 99m Tc and 123 I biodistributions, providing absorbed dose differences between OLINDA and SADRs within the 10-31% range (ratios 0.9 and 1.3 for 99m Tc and 123 I, respectively). Liver is involved in the biodistribution of 123 I with an also low difference equal to 31% (ratio 1.3). Liver that is not a self-irradiating organ in the biodistribution of 99m Tc, rises its difference (OLINDA vs SADRs) up to 135% (ratio 2.4).
The results of the absorbed dose differences between individualized S-values and SADRs are much lower as expected. More specifically, the differences in doses to kidneys (Svalues vs SADRs) are 5-6% (ratios 1.1 and 0.9) for these two radiopharmaceuticals, while the differences in doses to liver are 1.5% and 9.9% (ratios 1 and 0.9) for 99m Tc and 123 I, respectively. Finally, in the case of brain as a target organ: (a) for 123 I it is not irradiated by surrounding organs and thus, the absorbed dose is low, with differences between OLINDA and S-values up to 34%. This percentage is reduced to 11% when comparing S-values and SADRs, and (b) for 99m Tc where the skull acts as a source, there is a bigger difference between OLINDA and SADRs (58%) which is reduced to 15% when comparing S-values with SADRs. This trend is depicted in the comparison of the ratios between OLINDA, S-values, and SADRs in Fig. 5 , highlighting the need for further dosimetry studies taking into consideration the anatomical variations for cross-irradiating target organs. The highest differences between OLINDA and SADRs, on absorbed doses to target-only organs, show the impact of the anatomical variations on the dosimetry assessment. OLINDA values derive from standardized anatomical models, however, the contribution of the several source organs to a nonself-irradiated organ is crucial. The total absorbed dose to a targetonly organ is influenced by the contribution of several source organs (neighboring or no). When individualized S-values are used, we overcome this limitation to accurately quantify the absorbed dose. The SADR metric seems to provide absorbed doses very similar to the doses from individualized S-values (Fig. 5) , providing a flexible method for organ dosimetry assessment in different anatomies.
We found similar differences in the absorbed doses for phantom 6 (representing a 14-yr-old girl), which were up to approximately 55%. Such differences are within an expected range, as the OLINDA's S-values are based on standardized mathematical models that use geometrical shapes for organ modeling, which leads to large differences in the total anatomical characteristics. Furthermore, pediatric S-values in OLINDA are calculated by rescaling the adult predefined values, which imports additional uncertainty in the final dose assessment. Furthermore, Divoli et al. 44 compared S-values between MC simulations and OLINDA/EXM and found that differences in the mean absorbed doses were approximately 140% when realistic cumulative activity was used but decreased to less than 26% after mass correction.
We propose the SADR method, which accounts for the biodistribution of the radiopharmaceutical over time as well as the patient's specific anatomy, as an alternative method for calculating internal radionuclide organ absorbed doses. In addition to considering the differences in the organ masses and the patient's anatomy, the dosimetric results in this study of pediatric phantoms are within the range reported previously. For example, Marine et al., 24 reported differences in SAFs of approximately 10-33% among adult men with normal body mass indices. Traino et al., 45 studied the influence of total body mass on the scaling of S-values for therapeutic radionuclides, reporting differences of up to 36% in red marrow, which were likely due to cross-irradiation. Kramer et al., 23 in their comparison of the effective doses of internal photon irradiation between voxel-based and stylized models, found increases of up to 60%, 37%, 25%, and 15% for the liver, bones, lungs, and thyroid, respectively. Providing SADRs for a list of radiopharmaceuticals and a large population of anthropomorphic models can result in more accurate personalized dosimetry. Our ultimate goal is to create a database of SADRs that can be used to match any patient to the best anatomical model in the database according to characteristics such as weight, height, age, gender, and/or CT information, thereby providing more accurate, patient-specific organ absorbed doses for a specific examination. The database will include simulated dosimetric data for a variety of pediatric phantoms representing patients who are 2-15 yr old and who have several unique anatomical characteristics. For the extraction of personalized data on absorbed doses per organ, each pediatric patient will be matched to the most relevant phantom in the database on the basis of anatomical characteristics (e.g., age, weight, height, body mass index, gender, CT data). This approach differs from the current paradigm, whereby pediatric patient-specific dose estimates are based on rescaling the masses of specific models representing 1-, 5-, 10-, and 15-yr-old patients.
CONCLUSION
In this study, the SADR methodology was introduced and validated for personalized internal radionuclide dosimetry, revealing differences in absorbed doses in several organs with anatomical differences, even in patients with similar body weights. A pediatric dosimetry dataset was created for commonly used radiopharmaceuticals in NM for a set of six pediatric models. The GATE MC toolkit was initially validated to provide high accuracy compared with previously published data for internal dosimetry applications. The introduced metric of SADR was used to extract the absorbed doses per organ for two different radiopharmaceuticals and was compared to the absorbed doses calculated with the standard OLINDA/ EXM dosimetry software and from S-values that were calculated in the same model as the SADRs. We found large differences between SADRs and OLINDA/EXM values (up to 60%), as the S-values in OLINDA/EXM are based on standardized mathematical phantoms. We found smaller differences when the doses extracted from SADRs were compared with doses extracted from individualized S-values. Anatomical variations in children aged 5-15 yr must be considered to ensure accurate dosimetry. For all the studied models, SADRs varied up to approximately 90% with changes in age. The developed dataset provides the advantage of having an SADR for each target organ of interest for a specified radiopharmaceutical, considering all the anatomical characteristics of the phantom used to calculate the SADR. This approach reduces much of the need to simulate individualized S-values for every source organ for every patient to achieve more accurate dosimetry. The electron contribution to the absorbed doses should be also studied for the extraction of SADRs for the implementation of full dosimetry per radionuclide. In principle, the contribution of gamma and electron deposited energy should be considered in each target organ. We previously presented the concept of calculating the absorbed dose in organs from the rest of the organs simultaneously in preclinical applications. 46 The radiopharmaceuticals investigated in that study included both beta and gamma emitters. The SADR dataset should be extended to a variety of pediatric models for every radiopharmaceutical (including electronemitting radiopharmaceuticals) used in pediatric applications. Using this database, radiologists could match each new patient to a phantom on the basis of CT data, MRI data, and/ or parameters such as age, gender, weight, and height, and then use the SADRs to calculate the absorbed doses per organ. Our ultimate goal is to extend this dataset to a large database of NM examinations for the pediatric population, in whom the risks of exposure to ionizing radiation are of great concern. 
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